Xencor Inc (XNCR) stock
XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30194% above fair value
$34.39−0.11 (-0.32%)
Close on Nov 18, 2026Market cap $2.56BP/E –Yield –
Xencor pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Xencor's pe ratio was 70.0× on Jan 31, 2023, against 106.9× a year earlier. Over the last 3 years it ranged from 12.6× to 106.9×, with a median of 52.6×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2023 | Jan 31, 2023 | 70.0× | +14.6 |
| 2022 | Dec 30, 2022 | 55.4× | −51.5 |
| 2021 | Oct 29, 2021 | 106.9× | +43.4 |
| 2020 | Apr 30, 2020 | 63.5× | +6.2 |
| 2019 | Dec 31, 2019 | 57.3× | −2.6 |
| 2017 | Jul 31, 2017 | 59.9× | +32.5 |
| 2016 | Dec 30, 2016 | 27.4× | – |
See a number that looks wrong?